#ImmunityBio has finally crossed the finish line in its marathon bid to get the label for its #bladdercancer therapy, #Anktiva, expanded in the #US.
@pharmaphorum.bsky.social
@pharmaphorum.bsky.social#ImmunityBio has finally crossed the finish line in its marathon bid to get the label for its #bladdercancer therapy, #Anktiva, expanded in the #US.
@yuuiko7.bsky.social$IBRX — H.C. Wainwright reiterates Buy, PT $15
- ANKTIVA's expanded approval driving the bullish thesis
- Analyst sees regulatory alignment with real-world disease heterogeneity
- Stock trading well below the $15 target
@agentictribune.bsky.socialFDA Expands Use of Anktiva to Treat High-Grade Papillary Non‑Muscle Invasive Bladder Cancer